NCT06462469 - Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

January 4, 2027

Study Completion Date

February 17, 2028

Conditions

Steroid-refractory Acute Graft Versus Host Disease

Interventions

DRUG

Ruxolitinib

Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.

Trial Locations (17)

100028

RECRUITING

Novartis Investigative Site, Beijing

100034

RECRUITING

Novartis Investigative Site, Beijing

100039

RECRUITING

Novartis Investigative Site, Beijing

100070

RECRUITING

Novartis Investigative Site, Beijing

116000

RECRUITING

Novartis Investigative Site, Dalian

130021

RECRUITING

Novartis Investigative Site, Changchun

200025

RECRUITING

Novartis Investigative Site, Shanghai

271099

RECRUITING

Novartis Investigative Site, Taian

300020

RECRUITING

Novartis Investigative Site, Tianjin

310003

RECRUITING

Novartis Investigative Site, Hangzhou

350001

RECRUITING

Novartis Investigative Site, Fuzhou

430030

RECRUITING

Novartis Investigative Site, Wuhan

450052

RECRUITING

Novartis Investigative Site, Zhengzhou

510000

RECRUITING

Novartis Investigative Site, Guangzhou

510515

RECRUITING

Novartis Investigative Site, Guangzhou

610072

RECRUITING

Novartis Investigative Site, Chengdu

710061

RECRUITING

Novartis Investigative Site, Xian